StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
JAGXBullishCorporate Developmentsnews
Medium materiality6/10

Jaguar Health targets MVID NDA by mid-2027 with ACG 2026 abstract

Sep 29, 2026, 4:41 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive sentiment from abstract acceptance and NDA timeline may lift expectations for regulatory milestones and potential market opportunities, though data are preliminary and upside depends on subsequent confirmatory results.

AI summary

What happened, with direct paths to the underlying reporting

Jaguar Health's Napo Pharmaceuticals announced an abstract on preliminary crofelemer powder data for SBS-IF to be shown at ACG 2026, signaling ongoing progress in its rare-disease intestinal failure program. The company also reaffirmed a mid-2027 NDA submission target for MVID, presenting a potential near-term regulatory catalyst and possible long-term commercial upside if results are favorable.

  • Abstract accepted for crofelemer SBS-IF study at ACG 2026.
  • NDA filing target for MVID remains mid-2027.
  • Ongoing MVID/SBS-IF program remains Jaguar's focus.
  • Napo Pharmaceuticals aligns on crofelemer regulatory path.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event